A detailed history of Frazier Life Sciences Management, L.P. transactions in Hille Vax, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 10,617,062 shares of HLVX stock, worth $20.2 Million. This represents 1.01% of its overall portfolio holdings.

Number of Shares
10,617,062
Previous 10,617,062 -0.0%
Holding current value
$20.2 Million
Previous $154 Million 87.83%
% of portfolio
1.01%
Previous 9.05%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$11.86 - $15.93 $9.91 Million - $13.3 Million
835,590 Added 8.54%
10,617,062 $154 Million
Q1 2023

May 15, 2023

BUY
$14.73 - $18.18 $340,454 - $420,194
23,113 Added 0.24%
9,781,472 $162 Million
Q3 2022

Nov 14, 2022

BUY
$10.5 - $22.01 $4.96 Million - $10.4 Million
472,677 Added 5.09%
9,758,359 $167 Million
Q2 2022

Aug 10, 2022

BUY
$8.7 - $20.18 $80.8 Million - $187 Million
9,285,682 New
9,285,682 $101 Million

Others Institutions Holding HLVX

About HilleVax, Inc.


  • Ticker HLVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,427,200
  • Market Cap $63.5M
  • Description
  • HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
More about HLVX
Track This Portfolio

Track Frazier Life Sciences Management, L.P. Portfolio

Follow Frazier Life Sciences Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.